The Percentage of ALK-Positive Cells and the Efficacy of First-Line Alectinib in Advanced Non-small Cell Lung Cancer: Is it a novel factor for stratification? (Turkish Oncology Group Study)

Alectinib, Crizotinib, Medicine, Internal medicine, Lung cancer, ALK inhibitor, Oncology, Tyrosine-kinase inhibitor, Clinical endpoint, Gastroenterology, Cancer, Randomized controlled trial